Virax Biolabs Group’s (VRAX) Buy Rating Reaffirmed at HC Wainwright

Virax Biolabs Group (NASDAQ:VRAX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $1.00 price target on the stock, down from their previous price target of $3.00. HC Wainwright’s price target would indicate a potential upside of 165.96% from the stock’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Stock Performance

Shares of Virax Biolabs Group stock traded up $0.01 on Friday, hitting $0.38. 38,985 shares of the company’s stock traded hands, compared to its average volume of 426,657. Virax Biolabs Group has a 52-week low of $0.31 and a 52-week high of $2.61. The firm’s 50-day moving average is $0.44 and its 200 day moving average is $0.63.

Virax Biolabs Group (NASDAQ:VRAX) last issued its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.